$17.84
1.519.25%
Last update: Nov 9, 7:52 PM
Summit Therapeutics Inc
SMMTNASDAQ
The average analyst price target for Summit Therapeutics is $31.86, 79.0% above the current price. Of 17 analysts, 13 rate it Buy and 4 Hold. Targets range from $11.90 to $44. The latest change came on Oct 1, 2026, when Barclays raised its price target on Summit Therapeutics from $18 to $20 and kept an Equal-Weight rating.
Price Target Range — 12 Quarters
Analyst Consensus — 17 Analysts
Rating Trend — Last 9 Months
